CD276 and metastatic prostate carcinoma: Amori et al. discovered that high B7-H3 expression was more often detected in patients with metastatic prostate carcinoma than in individuals with localized carcinoma; thus, B7-H3 might be a beneficial biomarker for extremely aggressive metastatic prostate cancer [33].